默克調升營收預測，受惠於新藥銷售成長動能 (MRK:NYSE)
· seekingalpha.com
默克第二季財報優於預期，主因 Keytruda 與 Winrevair 銷售亮眼；營收成長 5% 並上修全年展望。
Merck (MRK) reported second-quarter results that topped Wall Street expectations, driven by continued strength in its blockbuster cancer drug Keytruda, as well ...